Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-022 in R/R PCNSL and SCNSL
NCT04438044Phase 2Unknown
- Sponsor
- InnoCare Pharma
- Start
- Jun 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in primary central nervous system lymphoma (PCNSL), secondary central nervous system lymphoma (SCNSL), sponsored by InnoCare Pharma. Status: unknown.
02
Drugs
orelabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)secondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on NCT04438044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04438044.